Genpharm’s Board is comprised of Senior Executives from several industries including R&D, Biotech, Pharmaceutical, Financial Services, and Management. Through their Executive Board memberships on several organizations and vast management experience, they provide strategic guidance to Genpharm and its partners in MENAT.
- Former Managing Director at Examon MENA
- Former Managing Director at Farbro Group
- Former General Manager at Janssen Cilag ME
- Honored by Rotary several times a Paul Harris Fellow for meeting outstanding personal, professional standards and charitable work
With over 30 years in the pharmaceutical industry, he has ample experience in bringing rare disease novel therapies to market, Kamel has held multiple Managing Director positions in several companies.
We are the first company to inroduce gene therapy into the MENA Region. The space is very promising since the region allows NPS and fast track approvals. After the FDA and or EMA approval, we are the first market to provide access to these innovative therapies. Since most diseases are pediatric and degenerative, early diagnosis, and treatment are ciritical. We are very proud to support patients in the region to improve their prognosis.
- Former VP Intercontinental Merck
- Former Middle East and Eastern Europe Head at Serono
- Launched and managed operations for several Biotech and rare disease products
- Wide expertise in emerging markets
- Active member of YPO and several industry associations
With more than 24 years of regional experience in Senior Executive roles, Karim has launched and managed operations for several Biotech and rare disease companies in Emerging Markets.
We are driven by a passion to do good and impact as many lives as we can. This is the legacy we would like to be remembered for. Working in the rare disease space, we are fortunate and very well positioned to be able to do so by relentlessly pushing throughobstacles and boundaries, facilitating diagnosis and access to the best available treatments.
- Former Chairman at Santhera Therapeutics
- Board of Directors Member at Jazz Pharmaceuticals
- Board of Directors Member at MindMaze
- Former General Partner and Member of the Executive Board of Merck KGaA
- Held senior positions in Marketing, Strategy & BD at UCB, Sanofi & others
- Board Member at Calmaste Sciences
- Former CEO of Sterling Natural Science and Sopherion Thx
- Former Faculty member Harvard Medical School and The Children’s Hospital-Boston
Mr. Ashkar is a recognized published author in many prestigious journals including Science, JBC, and JI. He is also a holder of multiple international patents.
- Former CEO and President of Silence Therapeutics
- Former CEO and President of Orchard Therapeutics
- Over 20 years of experience in bringing rare disease drugs to market
- Former Member of the Board of American Alliance of Regenerative Medicine (ARM)
- Former Chief Commercial
- Former Head EMEA region Shire Human Genetic Therapies
- Former Commercial Director EMEA for Chiron & Pathogenesis
As a passionate advocate of need for novel treatments for patient communities living with rare or specialized diseases around the world, I have seen first-hand the difference that the Genpharm team are making for patients suffering life-limiting, devastating diseases in the Middle East, North African region...
- Former Managing Director at Examon MENA
- Former Managing Director at Farbro Group
- Former General Manager at Janssen Cilag ME
- Honored by Rotary several times a Paul Harris Fellow for meeting outstanding personal, professional standards and charitable work
With over 30 years in the pharmaceutical industry, he has ample experience in bringing rare disease novel therapies to market, Kamel has held multiple Managing Director positions in several companies.
We are the first company to inroduce gene therapy into the MENA Region. The space is very promising since the region allows NPS and fast track approvals. After the FDA and or EMA approval, we are the first market to provide access to these innovative therapies. Since most diseases are pediatric and degenerative, early diagnosis, and treatment are ciritical. We are very proud to support patients in the region to improve their prognosis.
- Former VP Intercontinental Merck
- Former Middle East and Eastern Europe Head at Serono
- Launched and managed operations for several Biotech and rare disease products
- Wide expertise in emerging markets
- Active member of YPO and several industry associations
With more than 24 years of regional experience in Senior Executive roles, Karim has launched and managed operations for several Biotech and rare disease companies in Emerging Markets.
We are driven by a passion to do good and impact as many lives as we can. This is the legacy we would like to be remembered for. Working in the rare disease space, we are fortunate and very well positioned to be able to do so by relentlessly pushing throughobstacles and boundaries, facilitating diagnosis and access to the best available treatments.
- Former Chairman at Santhera Therapeutics
- Board of Directors Member at Jazz Pharmaceuticals
- Board of Directors Member at MindMaze
- Former General Partner and Member of the Executive Board of Merck KGaA
- Held senior positions in Marketing, Strategy & BD at UCB, Sanofi & others
- Board Member at Calmaste Sciences
- Former CEO of Sterling Natural Science and Sopherion Thx
- Former Faculty member Harvard Medical School and The Children’s Hospital-Boston
Mr. Ashkar is a recognized published author in many prestigious journals including Science, JBC, and JI. He is also a holder of multiple international patents.
- Former CEO and President of Silence Therapeutics
- Former CEO and President of Orchard Therapeutics
- Over 20 years of experience in bringing rare disease drugs to market
- Former Member of the Board of American Alliance of Regenerative Medicine (ARM)
- Former Chief Commercial
- Former Head EMEA region Shire Human Genetic Therapies
- Former Commercial Director EMEA for Chiron & Pathogenesis
As a passionate advocate of need for novel treatments for patient communities living with rare or specialized diseases around the world, I have seen first-hand the difference that the Genpharm team are making for patients suffering life-limiting, devastating diseases in the Middle East, North African region...